The exercise period for CLS warrants of series TO 7 begins today
In June 2024, Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) carried out a rights issue of shares and warrants of series TO 7 B (the “Rights Issue”). The exercise period for the warrants begins today, November 11, 2024 and runs up to and including November 22, 2024. One (1) warrant entitle the holder to subscribe for one (1) new B-share in CLS. The subscription price per B-share that is subscribed for through exercising the warrants has, in accordance with the terms and conditions for the warrants, been set to SEK 3.68. If all warrants are exercised, CLS will receive approximately SEK 22.4 million before issuing costs.
Summary of instructions and important dates
Holders of warrants who wish to exercise warrants to subscribe for B-shares shall give notice regarding such exercise before the end of November 22, 2024. Warrants that have not been exercised on or before November 22, 2024, will expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including November 20, 2024.
Detailed information and instructions for subscription
Exercise of nominee-registered warrants
Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before November 22, 2024 as different nominees have different processing times.
Exercise of directly registered warrants
Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing AB, no later than November 22, 2024.
The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.clinicallaser.se, www.nordic-issuing.se, www.redeye.se). Please note that payment for the new shares must be received by Nordic Issuing no later than November 22, 2024 in accordance with the instructions on the application form.
Trading in TO 7 B
Holders who do not wish to exercise their warrants may sell them on Nasdaq First North Growth Market. The warrants are traded up to and including November 20, 2024 under the short name CLS TO 7 B and with ISIN SE0022242319. Warrants that are not exercised on November 22, 2024 at the latest or sold on November 20, 2024 at the latest will expire without value.
Outcome and delivery of new shares
The outcome of the exercise of warrants will be published via a press release on or around November 26, 2024. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the exercise of warrants have been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into ordinary B-shares in CLS.
Number of warrants and possible proceeds
The number of warrants amounts to 6,080,000. Upon full exercise of all warrants, CLS will receive approximately SEK 22.4 million before issuing costs. If all warrants are used to subscribe for B-shares, the number of B-shares in CLS will increase by 6,080,000 B-shares and the share capital will increase by approximately SEK 14,042,247.51.
Complete terms and conditions for the warrants
Complete terms and conditions for the warrants and the prospectus prepared by the Board of Directors of CLS in connection with the rights issue in 2024 are available on the Company's website. The prospectus is also available on Swedish Financial Supervisory Authority 's website www.fi.se.
Investor presentations
CLS will present at Redeye’s investor event Medtech & Diagnostics on November 13, 2024. Information about the event is available on Redeye's website.
Disclosure to investors pursuant to the act (2023:560) on the Screening of Foreign Direct Investments
The Act (2023:560) on the Screening of Foreign Direct Investments ("FDI Act") applies to the Company's operations. In the event that the exercise of warrants would result in an investor, after the investment, directly or indirectly, holding votes representing or exceeding any of the thresholds of 10, 20, 30, 50, 65, or 90 percent of the votes in the company, the investor is required to notify their investment to the Inspectorate for Strategic Products in accordance with the FDI Act
Advisers
Redeye AB is acting as financial adviser and Foyen Advokatfirma is acting as legal adviser to CLS in connection with the exercise of warrants series TO 7 B. Nordic Issuing AB is acting as issuing agent.
For more information, please contact
Dan J Mogren, CEO Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se